CYSVIEW KIT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cysview Kit, and when can generic versions of Cysview Kit launch?
Cysview Kit is a drug marketed by Photocure Asa and is included in one NDA. There are three patents protecting this drug.
This drug has twenty-nine patent family members in seventeen countries.
The generic ingredient in CYSVIEW KIT is hexaminolevulinate hydrochloride. One supplier is listed for this compound. Additional details are available on the hexaminolevulinate hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Cysview Kit
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 19, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CYSVIEW KIT?
- What are the global sales for CYSVIEW KIT?
- What is Average Wholesale Price for CYSVIEW KIT?
Summary for CYSVIEW KIT
| International Patents: | 29 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Clinical Trials: | 3 |
| Patent Applications: | 92 |
| DailyMed Link: | CYSVIEW KIT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CYSVIEW KIT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for CYSVIEW KIT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dr. Te Vuong | Phase 2 |
| KARL STORZ Endoscopy-America, Inc. | Phase 2 |
| KARL STORZ Endoscopy-America, Inc. | Phase 3 |
US Patents and Regulatory Information for CYSVIEW KIT
CYSVIEW KIT is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of CYSVIEW KIT is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting CYSVIEW KIT
Neoadjuvant therapy for bladder cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
Method of photodynamic therapy (PDT) for bladder cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
Neoadjuvant therapy for bladder cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CYSVIEW KIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Photocure Asa | CYSVIEW KIT | hexaminolevulinate hydrochloride | FOR SOLUTION;INTRAVESICAL | 022555-001 | May 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CYSVIEW KIT
When does loss-of-exclusivity occur for CYSVIEW KIT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16372573
Patent: Neoadjuvant therapy for bladder cancer
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2018012009
Patent: terapia neoadjuvante para câncer de bexiga
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 08551
Patent: TRAITEMENT NEOADJUVANT DU CANCER DE LA VESSIE (NEOADJUVANT THERAPY FOR BLADDER CANCER)
Estimated Expiration: ⤷ Sign Up
China
Patent: 8601836
Patent: 用于膀胱癌的新辅助疗法 (Neoadjuvant therapy for bladder cancer)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 89717
Patent: TRAITEMENT NÉOADJUVANT DU CANCER DE LA VESSIE (NEOADJUVANT THERAPY FOR BLADDER CANCER)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 26086
Estimated Expiration: ⤷ Sign Up
Patent: 18537514
Patent: 膀胱癌のための術前補助療法
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 18124868
Patent: НЕОАДЪЮВАНТНАЯ ТЕРАПИЯ ДЛЯ РАКА МОЧЕВОГО ПУЗЫРЯ
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 180094987
Patent: 방광암에 대한 신보조 요법
Estimated Expiration: ⤷ Sign Up
United Kingdom
Patent: 1522309
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering CYSVIEW KIT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| France | 2777782 | SOLUTION POUR LA PREPARATION D'UNE SUBSTANCE PHARMACEUTIQUE POUR LE DIAGNOSTIC ET/OU LE TRAITEMENT DE LESIONS TISSULAIRES | ⤷ Sign Up |
| Hungary | 225148 | ESTERS OF 5-AMINOLEVULINIC ACID AS PHOTOSENSITIZING AGENTS IN PHOTOCHEMOTHERAPY OR DIAGNOSIS, PRODUCTS AND KITS COMPRISING THEREOF AND METHOD OF IN VITRO DIAGNOSIS BY THEIR USING | ⤷ Sign Up |
| China | 1137087 | ⤷ Sign Up | |
| Norway | 974163 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CYSVIEW KIT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0820432 | SPC024/2002 | Ireland | ⤷ Sign Up | SPC024/2002: 20041230, EXPIRES: 20160614 |
| 0820432 | 07C0010 | France | ⤷ Sign Up | PRODUCT NAME: AMINOLEVULINATE DE METHYLE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 30885 20060919; FIRST REGISTRATION: SE - 16338 20010615 |
| 0820432 | SPC019/2008 | Ireland | ⤷ Sign Up | SPC019/2008: 20090219, EXPIRES: 20190916 |
| 0820432 | SPC/GB05/044 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: HEXYL AMINOLEVULINATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY HEXYL AMINOLEVULINATE HYDROCHLORIDE; REGISTERED: SE 19227 20040917; UK PL 18952/0003 20050714 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
